News

Article

Bausch + Lomb receives CPT Category 1 Code for triamcinolone acetonide injectable suspension (XIPERE) from American Medical Association

XIPERE is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis.

(Image Credit: AdobeStock/Timon)

(Image Credit: AdobeStock/Timon)

Bausch + Lomb announced the American Medical Association (AMA) has confirmed assignment of the Category 1 Current Procedural Terminology (CPT) code for its triamcinolone acetonide injectable suspension XIPERE. The company announced the assignment in a press release.1

The AMA has granted the CPT code 67516 with support from the American Academy of Ophthalmology (AAO) and the American Society of Retina Specialists (ASRS), according to Bausch + Lomb.

“The category 1 code will help facilitate better access and adoption of XIPERE and its unique suprachoroidal injection method, which enables targeted delivery of the medication,” said Andrew Stewart, president, Global Pharmaceuticals and International Consumer, Bausch + Lomb in the press release. “We greatly appreciate the support and guidance AAO and ASRS provided throughout this process.”

The new CPT Category 1 code and their descriptors covering the XIPERE procedure will be included in a future edition of the CPT Codebook and will be effective on January 1, 2024, according to the company. The XIPERE J-code J3299 became effective in July 2022.1

XIPERE is the first and only therapy available in the United States that utilizes the suprachoroidal space to treat patients suffering from macular edema associated with uveitis, and became commercially available in March 2022.1

References:
  1. Bausch + Lomb Receives CPT Category 1 Code for XIPERE® (Triamcinolone Acetonide Injectable Suspension) From the American Medical Association. Press Release. Released November3, 2023. Accessed November 7, 2023. https://www.bausch.com/news/?id=189

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.